Clinicopathological characteristics and prognostic factors for canine multicentric non‐indolent T‐cell lymphoma: 107 cases

Purzycka, K and Peters, L M and Desmas, I and Davies, O and Chang, Y M and Lara‐Garcia, A (2020) Clinicopathological characteristics and prognostic factors for canine multicentric non‐indolent T‐cell lymphoma: 107 cases. Veterinary and Comparative Oncology. ISSN 1476-5810

[img]
Preview
Text
13017_GOLD VoR.pdf - Published Version
Available under License Creative Commons Attribution.

Download (238kB) | Preview
Official URL: https://doi.org/10.1111/vco.12589

Abstract

Canine lymphoma, as the most common haematopoietic malignancy, encompasses a group of heterogeneous diseases and even within the T-cell immunophenotype, differences in clinical presentation and responses to treatment exist. The aim of this retrospective study was to determine outcomes and prognostic factors of 107 dogs with multicentric non-indolent T-cell lymphoma (TCL) receiving lomustine-based (70%) and non-lomustine-based (30%) treatment. The majority were Labradors, Boxers, mixed-breed dogs and Dogue de Bordeaux. Eighty-six percent were substage b, 77% had mediastinal involvement, 15% had suspected bone marrow involvement and 12% had other extra-nodal sites of disease. The overall response rate to induction therapy was 80%; dogs receiving procarbazine in the induction protocol (P = .042), dogs with neutrophil concentration below 8.7 × 10e9 /L (P = .006) and mitotic rate below 10 per 5 high power field (P = .013), had greater response rates. Median progression-free survival (PFS) for the first remission was 105 days; lack of expression of CD3 on flow cytometry (P < .0001) and pretreatment with steroid (P = .012) were significantly associated with shorter PFS. Median overall survival time (OST) was 136 days; co-expression of CD79a (P = .002), lack of CD3 expression on flow cytometry, presence of anaemia (P = .007), and monocytopenia (P = .002) were predictive of shorter OST. Multicentric non-indolent TCL in dogs is an aggressive cancer with new possible prognostic factors.

Actions (Repository Editors)

View Item View Item